Worked in pharma industry for more than 20 years, 15 years homegrown MSD Talent, 8 years in position as District Manager in Central GMA and South Luzon territory adept in managing team while planning and implementing sales and marketing strategies.
Overview
18
18
years of professional experience
3
3
Certifications
Work History
District Sales Manager
Zuellig Pharma
07.2023 - Current
Directed operations for a team covering eight key territories, including South Luzon (Batangas, Cavite, Laguna, Quezon) and Metro Manila (Makati, Taguig, Parañaque, Las Piñas).
Successfully managed the Januvia Family Business Unit through a period of organizational retrenchment, effectively mitigating the decline of mature brands against aggressive generic competition.
Led the successful integration of new brands—Cialis, Kalium, and Humalog—into the district portfolio in 2024, resulting in double-digit growth across the district.
Oversaw the high-impact launch of Mounjaro in 2026 across eight major territories, including Makati, Pasig, and Manila.
Delivered over 65M in sales achievement within the first two months of the Mounjaro launch, surpassing the 2025 MAT sales history of the leading competitor, Ozempic (58M).
Orchestrated a Grand Launch event with 1,500 HCP participants, targeting over 2,000 specialists in Cardiology, Endocrinology, Nephrology, Diabetology, Internal Medicine, GP, Family Medicine, and Dermatology.
Drove sales output through targeted hospital inclusion, MD activation, and the development of Industrial accounts.
District Manager
MSD PHILS. INC.
01.2018 - Current
Managed a high-performing, all-women team of seven senior and tenured Professional Sales Representatives (PSRs) in a lean territory setup with a 1:4 ratio against competitors.
Led the district to become the #1 sales driver for the CVM Business Unit, contributing 25% of total sales (300M PHP).
Awarded the 2022 Top District MI (Face-to-face and VE) Achiever with a YTD performance of 129.75%.
Achieved 100% team success in 2022, with all seven PSRs exceeding their total sales performance targets.
Delivered a 7% increase in total Diabetes sales during the height of the pandemic (2021 vs. 2022).
Mitigated the decline of the Januvia Family against aggressive generic competition. Specifically grew the priority SKU, Janumet XR, by 1% as of June 2023, while the broader product family faced double-digit declines.